Evaluating prognostic parameters in women with uterine leiomyosarcoma. A clinicopathologic study.
OBJECTIVE
To evaluate the prognostic impact of different clinicopathologic parameters in patients with uterine leiomyosarcoma.


METHODS
Twenty-one patients with histologically proven uterine leiomyosarcoma were included in the analysis. Leiomyosarcomas were defined as uterine smooth muscle tumors with > or = 5 mitoses per 10 high-power fields and nuclear atypia and/or necrosis.


RESULTS
The median follow-up time was 47 months; 5-year overall survival was 41%. A univariate Cox model revealed that early tumor stage (P = .00001), age at diagnosis < 50 years (P = .02), absence of vascular space involvement (P = .04), low myometrial invasion (P = .006) and low histologic grade (P = .04) were associated with lengthened overall survival. Adjuvant radiotherapy and/or chemotherapy (P = .1) did not influence overall survival.


CONCLUSIONS
Early tumor stage, age at diagnosis < 50 years, absence of vascular space invasion, low myometrial invasion and low histologic grade were parameters of a good prognosis in women with uterine leiomyosarcoma. Adjuvant chemotherapy and/or radiotherapy showed no benefit in these patients.
Bodner
Klaus
K
Departments of Gynecology and Obstetrics, Gynecopathology and of Anesthesiology, University of Vienna Medical School, A-1090 Vienna, Währinger Gürtel 18-20, Austria.
Bodner-Adler
Barbara
B
Kimberger
Oliver
O
Czerwenka
Klaus
K
Leodolter
Sepp
S
Mayerhofer
Klaus
K
D000328:Adult; D000368:Aged; D000704:Analysis of Variance; D001707:Biopsy, Needle; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007044:Hysterectomy / Q000379:methods; D007890:Leiomyosarcoma / Q000401:mortality / Q000473:pathology* / Q000628:therapy*; D008875:Middle Aged; D009367:Neoplasm Staging; D011336:Probability; D011379:Prognosis; D016016:Proportional Hazards Models; D018714:Radiotherapy, Adjuvant; D012189:Retrospective Studies; D018570:Risk Assessment; D012494:Sampling Studies; D016019:Survival Analysis; D016896:Treatment Outcome; D014594:Uterine Neoplasms / Q000401:mortality / Q000473:pathology* / Q000628:therapy*